MiRXES is a Singapore-headquartered biotechnology company that translates research discoveries to deliver clinical diagnoses. MiRXES specializes in the development and delivery of microRNA-centric technology and services for a wide range of discovery and diagnostic applications.

Stories by MiRXES

Facing The Double Threat With Fortitude

By differentiating between the two diseases, MiRXES’ new Fortitude SARS-CoV-2 and flu A/B test could help countries face the ‘twindemic’ of flu and COVID-19.

Profiling A Panorama Of Pathologies

By targeting nearly 400 miRNAs linked to over 20 different diseases with a single product, MiRXES’ ID3EAL PanoramiR microRNA knowledge panel proves that it’s possible to achieve more with less.